Insiders Immutep ADR Nasdaq

Equities

Market Closed - Nasdaq Other stock markets 01:30:00 01/06/2024 am IST			5-day change	1st Jan Change
2.98 ^USD	+3.83%		+4.93%	+24.17%

17/05	Capital One Initiates Immutep at Overweight Rating With $10 Price Target	MT
15/05	Immutep Says Safety Lead-in Phase of Breast Cancer Study Yields 'Encouraging' Data	MT

Encouraging results for Immutep's cancer therapies	25/03	FI
Immutep Limited Appoints Florian Vogl as Chief Medical Officer	26/23/26	CI
Immutep Limited Announces Changes to the Board	11/23/11	CI
Immutep Appoints Frederic Triebel as Executive Director	13/22/13	CI
Immutep Limited Announces Executive Changes	18/22/18	CI
Immutep Limited Appoints Lucy Turnbull as Non-Executive Director	25/22/25	CI
Immutep Limited Announces Demise of Grant Chamberlain, Non-Executive Director	02/22/02	CI
Immutep Limited Announces Executive Changes	04/21/04	CI
Prima BioMed Ltd will Change its Name to Immutep Ltd	01/17/01	CI
Prima Biomed Limited Announces Cessation of Lucy Turnbull as Director	22/17/22	CI
Immutep Limited Announces Cessation of Mr. Albert Wong as Director	22/17/22	CI
Prima BioMed Ltd. Appoints Grant Chamberlain as Non-Executive Director	21/17/21	CI
Prima Biomed Ltd. Announces Formation of Clinical Advisory Board	01/17/01	CI
Prima Biomed Ltd. Appoints Jay Campbell as General Manager, US Operations	07/17/07	CI
Prima Biomed Ltd. Announces Executive Changes	08/16/08	CI
Stuart Roberts Appoints Stuart Roberts as Global Head of Investor Relations	20/15/20	CI
Frédéric Triebel Joins Prima Biomed Ltd as its New Chief Scientific Officer and Chief Medical Officer	17/14/17	CI
Prima Biomed Ltd. Announces Executive Changes	09/14/09	CI
Prima BioMed Ltd Appoints Professors Eric Pujade-Lauraine, Christian Marth and Ignace Vergote to its Clinical Advisory Board	25/14/25	CI
Bradley J. Monk to Join Prima Biomed's Clinical Advisory Board	20/14/20	CI

No results for this search